Kabra Drugs (BOM:524322) 3-Year EBITDA Growth Rate : -131.60% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Kabra Drugs 3-Year EBITDA Growth Rate?

Kabra Drugs's EBITDA per Share for the three months ended in Dec. 2023 was ₹-0.25.

During the past 3 years, the average EBITDA Per Share Growth Rate was -131.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 16.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kabra Drugs was 57.70% per year. The lowest was -131.60% per year. And the median was -5.25% per year.

Competitive Comparison of Kabra Drugs's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Kabra Drugs's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kabra Drugs's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kabra Drugs's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kabra Drugs's 3-Year EBITDA Growth Rate falls into.

Kabra Drugs 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Kabra Drugs (BOM:524322) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Kabra Drugs 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Kabra Drugs's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Kabra Drugs (BOM:524322) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kabra Drugs Ltd (BOM:524322) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Swaminathan Street, No:3, 2nd Floor, West Mambalam, Chennai, TN, IND, 600033

Website

http://www.kabradrugs.com

Kabra Drugs Ltd is an India-based drug manufacturing company. It is engaged in the business of Permaculture manufacturing and trading in pharma related products. Geographically, all the company operations are carried out in India. It generates revenue from the sale of materials principally in India. The company plant for manufacturing the drugs is located in the Indian state of Madhya Pradesh. Its products include Cardiovascular Drugs, Anti-Infective Drugs, Oncology Drugs, Gastroenterologic Drugs, Hormonal Drugs, etc.

Kabra Drugs (BOM:524322) Headlines

No Headlines